According to WEHT, Dick Durbin, the Majority Whip of the United States Senate, has criticized the tobacco policy of the U.S. Food and Drug Administration (FDA).
Senator Durbin stated that the FDA has failed to protect children from the harm caused by e-cigarettes, calling it "unacceptable." He called on the Biden administration to promptly implement a rule that prohibits the production and sale of menthol cigarettes and flavored cigars.
Deborah Bin expressed, "I went to the Senate today and said, 'We have had enough."
For the sake of our children, the FDA needs to take action... I believe it is now time for these flavored cigarettes to be phased out from the market on all levels.
Devin has repeatedly criticized the FDA for its belated review of pre-market tobacco applications (PMTA) for e-cigarette manufacturers, with a federal court deadline set for September 2021.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
